OncoNano to Present New Preclinical Data at AACR 2026

Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform

Apr. 17, 2026 at 11:26pm

Got story updates? Submit your updates here. ›

An extreme close-up of a translucent, ghostly molecular structure with glowing lines and shapes, conceptually representing the internal mechanisms of a sophisticated cancer drug delivery system.Cutting-edge drug delivery technology aims to improve the targeting and release of cancer-fighting payloads within the tumor microenvironment.Dallas Today

OncoNano Medicine, Inc., a clinical-stage biotechnology company, will present new preclinical data at the American Association for Cancer Research (AACR) 2026 conference. The data will showcase the antigen-independent delivery, differentiated efficacy, and broad payload versatility of the company's proprietary ultra pH-sensitive polymer-drug conjugate technology, known as the ON-BOARD platform.

Why it matters

OncoNano's technology aims to overcome key limitations of existing drug delivery approaches, including reliance on tumor-associated antigens and off-tumor toxicities. The presentation of these promising preclinical results at a major cancer research conference could signal advancements in the company's efforts to develop more effective and targeted cancer therapies.

The details

The posters to be presented at AACR 2026 will highlight the capabilities of OncoNano's ON-BOARD platform, which utilizes ultra pH-sensitive polymer-drug conjugates to enable antigen-independent delivery and differentiated efficacy. The technology is designed to improve the targeting and release of a variety of therapeutic payloads within the tumor microenvironment.

  • The AACR 2026 conference will take place in April 2026.

The players

OncoNano Medicine, Inc.

A clinical-stage biotechnology company developing precision therapies using its proprietary ON-BOARD platform.

Got photos? Submit your photos here. ›

The takeaway

The presentation of OncoNano's promising preclinical data at AACR 2026 could signify advancements in the development of more effective and targeted cancer therapies that address the limitations of current drug delivery approaches.